800-826-HOPE (4673)

If you have been recently diagnosed with a kidney tumor or looking for a second opinion, talk to us. It's important to take action as quickly as possible. Our world-class team of kidney and urological cancer specialists can walk you through the process, address your concerns and create a personalized treatment plan designed to give you the best possible results.

Why Choose Us

When kidney cancer is detected early, there are more treatment options available and survival rates are excellent.

City of Hope brings together treatment and research expertise from multiple disciplines with an unmatched reputation for coordinate, compassionate care:

  • State-of-the-art screenings and diagnostic tools
  • Ultra-precise, robotic-assisted surgery using the da Vinci Surgical System  
  • Minimally invasive cryosurgery and radiofrequency ablation
  • Kidney-sparing procedures that minimizes quality of life impact
  • Radiation therapy, including Helical TomoTherapy
  • Next generation immunotherapy
  • Pioneering drug research and clinical trials
  • Exceptional family and patient support programs

Nationally Ranked Cancer Center

  • City of Hope is a nationally recognized as a leader in the research and treatment of kidney cancer.
  • We are one of the few facilities designated a Comprehensive Cancer Center by the National Cancer Institute.
  • For over a decade, U.S. News & World Report has named City of Hope one of the top cancer hospitals in America.

Request a Consultation

If you have been diagnosed with kidney cancer or are looking for a second opinion consultation about your treatment, request an appointment online or contact us at 800-826-HOPE. Please visit Making Your First Appointment for more information.


Care Team

City of Hope’s renowned physicians and researchers utilize the latest in technology and innovation to treat kidney cancer, coupled with our enduring belief in providing unparalleled compassionate care.

Urologic Oncologists

Kevin G. Chan, M.D.

Clinical Specialties

  • Urology
  • Urologic Oncology
Laura Crocitto, M.D., M.H.A.

Clinical Specialties

  • Urology
  • Urologic Oncology
Clayton S. Lau, M.D.

Clinical Specialties

  • Urology
  • Urologic Oncology
Bertram Yuh, M.D., M.S.H.C.P.M., M.I.S.M.

Clinical Specialties

  • Urology
  • Urologic Oncology
Jonathan Lim Yamzon, M.D.

Clinical Specialties

  • Urology
  • Urologic Oncology
Ali Zhumkhawala, M.D.

Clinical Specialties

  • Urology
  • Urologic Oncology

Medical Oncologists

Sumanta Kumar Pal, M.D.

Clinical Specialties

  • Medical Oncology
Przemyslaw W. Twardowski,

Clinical Specialties

  • Medical Oncology

Radiation Oncologist

Sagus Sampath, M.D.

Clinical Specialties

  • Radiation Oncology

At City of Hope, we design a kidney cancer treatment plan just for you that will deliver the best outcome possible.

Our entire team works together to bring you precise, state-of-the-art treatment options for kidney cancer, including:

City of Hope is a recognized leader in kidney cancer research, with one of the largest numbers of open kidney cancer clinical trials underway on the West Coast. We are constantly developing new therapies to eradicate your cancer and minimize side effects.

Our latest research includes new imaging techniques to better target tumors during surgery, several new drugs to stimulate the body's immune system to destroy cancer cells and experimental therapies that target cancer stem cells.

Browse through some of our clinical trials and research projects.

  • Kidney Cancer Database
  • SWOG S0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
  • Assessment of Bacteriomic Profiling and Other Biomarkers as Predictors of Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (VEGF-TKI)-Induced Diarrhea in Patients with Metastatic Renal Cell Carcinoma (mRCC)
  • PHII-122, NCI#9048: A Randomized Phase 2 Study of AMG 386 with or without Continued Anti-Vascular Endothelial Growth Factor (VEGF) Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib
  • ECOG-ACRIN E2810: Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
  • COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study
  • A Randomized Phase 2 Trial of Axitinib and TRCL105 Versus Axitinib Alone (Including a Lead-In Phase 1b Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma
  • Metastatic Renal Cell Cancer Registry (MaRCC Registry)
  • When you come to City of Hope, you automatically gain access to an unparalleled support services to help you and your family take each step in your kidney cancer treatment. Learn more about the resources listed below at our Living with Cancer and Supportive Care Medicine sites.
    • Managing side effects
    • Pain management
    • Navigating the health care system
    • Your emotional, social and spiritual health
    • Staying healthy and active
    • Healthy cooking and eating
    • Healing arts
    • Caregiver skills
    • Dealing with family, school or work stress
    Additional Resources




    We deliver exquisite care at the leading edge of cancer treatment. It takes the help of a lot of caring people to make hope a reality for our patients. City of Hope was founded by individuals' philanthropic efforts over 100 years ago. Their efforts - and those of our supporters today - have built the foundation for the care we provide and the research we conduct.

    For more information on supporting this specific program, please contact
    Or, you can make a gift to support all the research at City of Hope by donate online.


    City of Hope experts cover prevention, screening, treatment and other cancer topics on City of Hope’s Breakthrough’s blog.

    Back To Top